Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07598214

Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients

The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cancer Patients

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Faculty of Medicine

Banī Suwayf, 0000, Egypt

Location status: Recruiting

Location contact

beni suef university

CONTACT

About this study

The current study is a prospective randomized controlled clinical study that will be conducted on about 100 cancer patients.

Study duration The study will be conducted from January 2025 to September 2025

Study population Group I (control): includes 37 cancer patients administrating platinum compounds in their chemotherapeutic cycles as standard therapy.

Group II (Test group) includes 37 cancer patients administrating platinum compounds in their chemotherapeutic cycles as standard therapy plus 450 mg diosmin and 50 mg hesperidin combination orally twice daily.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy.

Exclusion criteria

  • -History of allergic reactions attributed to drugs in the study.
  • Pregnant women.
  • Life expectancy less than 6 months
  • Inability or unwillingness to comply with research protocols.
  • Cancer patients with impaired renal function (creatinine clearance < 50 mL/min)
  • Preexisting hearing loss.
  • Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.

Treatment and study plan

diosmin/hesperdin

Combination Product

combination of Diosmin and Hesperidin

Primary outcomes

  1. serum creatinine level

    Time frame: 6 months following treatment

    Serum creatinine will be measured in mg/dl every 2 weeks during the study period.

  2. blood urea level

    Time frame: 6 months following treatment

    blood urea levels will be measured in mg/dl every 2 weeks during the study period.

Secondary outcomes

  1. hemoglobin level

    Time frame: 6 months following treatment

    Hemoglobin levels will be measured in g/dl every 2 weeks during the study period.

Study contacts

Contact information is provided by the study sponsor or research team.

marwa mohsen, PhD

CONTACT

[email protected]

01202203223

Sponsors and collaborators

Lead sponsor

Beni-Suef University

Other

Registry information

Official study title

Evaluation of the Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients: A Randomized Controlled Trial

Acronym: Dios/Hes-PT

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 20, 2026
Registry last updated
May 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.